The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 6, 2001, Pages 11-16

  Coleman, Robert E ^a   Seaman, John J ^a,b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0034984095     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.24155     Document Type: Review

References (36)

1. Preclinical pharmacology of CGP 42′446, a new potent, heterocyclic bisphosphonate compound
2. Zoledronate (CGP-42′446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate
3. Effect of 1-year treatment with zoledronate (CGP 42446) on bone mineral density, bone mechanical properties, and biochemical markers in the ovariectomized rat
4. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys
5. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy - A pooled analysis of two randomized, controlled clinical trials
6. A phase 1, dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone lesions
7. A phase 1 open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
8. Zoledronic acid reduces skeletal related events in patients with osteolytic metastases: A double-blind, randomized, dose-response study
9. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
10. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
11. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
12. American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer
13. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases
14. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma
15. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system
16. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
17. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
18. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
19. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
20. Bisphosphonates in the reduction of metastases in breast cancer - Results of the extended follow-up of the first study population
21. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized, controlled trial
22. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
23. Oral pamidronate: Negative results from 3 double-blind, placebo-controlled trials in hypercalcemia, myeloma, and prevention of bone metastases
24. Post-operative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project-16
25. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: Results from National Surgical Adjuvant Breast and Bowel Project B-15
26. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes
27. Bone metastases
28. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases
29. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption
30. Morphometric evidence for bone resorption and replacement in prostate cancer
31. Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study
32. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
33. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
34. Zoledronic acid induces apoptosis of breast cancer cells in vitro - Evidence for additive and synergistic effects with taxol and tamoxifen
35. Bisphosphonates induce apoptosis in human breast cancer cell lines
36. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events